Lysosomal Storage Disorders: Molecular Basis and Therapeutic Approaches
Author:
Open Access
- 30 June 2021
- journal article
- editorial
- Published by MDPI AG in Biomolecules
- Vol. 11 (7) , 964
Abstract
Lysosomal storage disorders (LSDs) are a group of 60 rare inherited diseases characterized by a heterogeneous spectrum of clinical symptoms, ranging from severe intellectual disabilities, cardiac abnormalities, visceromegaly, and bone deformities to slowly progressive muscle weakness, respiratory insufficiency, eye defects (corneal clouding and retinal degeneration), and skin alterationsKeywords
This publication has 18 references indexed in Scilit:
- Newborn Screening for Fabry Disease in Northeastern Italy: Results of Five Years of ExperienceBiomolecules, 2021
- Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic DirectionsBiomolecules, 2021
- Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for ImprovementBiomolecules, 2021
- The rapidly evolving view of lysosomal storage diseasesEMBO Molecular Medicine, 2021
- The Release of a Soluble Glycosylated Protein from Glycogen by Recombinant Lysosomal α-Glucosidase (rhGAA) In Vitro and Its Presence in Serum In VivoBiomolecules, 2020
- Pompe Disease: New Developments in an Old Lysosomal Storage DisorderBiomolecules, 2020
- Rapid Clathrin-Mediated Uptake of Recombinant α-Gal-A to Lysosome Activates AutophagyBiomolecules, 2020
- Upregulation of Sortilin, a Lysosomal Sorting Receptor, Corresponds with Reduced Bioavailability of Latent TGFβ in Mucolipidosis II CellsBiomolecules, 2020
- Author Correction: Lysosomal storage diseasesNature Reviews Disease Primers, 2018
- The pathogenesis of lysosomal storage disorders: beyond the engorgement of lysosomes to abnormal development and neuroinflammationHuman Molecular Genetics, 2018